Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review

Published:2021-11-09 Issue:1 Volume:3 Page:276-290
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Alnassfan Tahera¹²,Cox‐Pridmore Megan J.¹²,Taktak Azzam³,Till Kathleen J¹^ORCID

Affiliation:

1. Department of Molecular and Clinical Cancer Medicine University of Liverpool Liverpool UK

2. Authors Tahera Alnassfan and Megan J. Cox‐Pridmore contributed equally to the review

3. Medical Physics and Clinical Engineering Royal Liverpool University Hospital Liverpool UK

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.311

Reference72 articles.

1. Mantle cell lymphoma and its management: where are we now?

2. Mantle Cell Lymphoma

3. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

4. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects

5. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Front‐line and second‐line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis;European Journal of Haematology;2024-04-25

2. Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface;Oncotarget;2024-04-12

3. Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study;Hematology Reports;2024-01-18

4. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma;International Journal of Clinical Oncology;2023-12-29

5. Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials;Cancer Medicine;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3